{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:32:17Z","timestamp":1793385137697,"version":"4.5.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":31,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pacific Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.apjo.2026.100380","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:29:00Z","timestamp":1791008940000},"page":"100380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Can Moderna's mRNA cancer vaccine for cutaneous melanoma be applicable to melanomas of the eye and ocular adnexa?"],"prefix":"10.1016","volume":"15","author":[{"given":"Shu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiu Ying Enne","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun D.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine J.","family":"Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianqun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis S.C.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apjo.2026.100380_bib1","unstructured":"Merck & Co., Inc. Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA\u00ae Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma [press release]. Rahway, NJ: Merck & Co.; 2026."},{"key":"10.1016\/j.apjo.2026.100380_bib2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-26-00835","article-title":"Intismeran autogene plus pembrolizumab versus pembrolizumab alone in high-risk resected melanoma: 5-year update of the randomized phase IIb KEYNOTE-942 Study","author":"Khattak","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apjo.2026.100380_bib3","author":"National Cancer Institute","year":"2026","journal-title":"SEER cancer stat facts melanoma skin. Surveillance epidemiology end results program"},{"key":"10.1016\/j.apjo.2026.100380_bib4","series-title":"Melanoma of the skin statistics","author":"Cancer Australia","year":"2025"},{"issue":"3","key":"10.1016\/j.apjo.2026.100380_bib5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4068\/cmj.2016.52.3.185","article-title":"Cutaneous Melanoma in Asians","volume":"52","author":"Kim","year":"2016","journal-title":"Chonnam Med J"},{"issue":"1","key":"10.1016\/j.apjo.2026.100380_bib6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","volume":"6","author":"Uveal melanoma. Jager","year":"2020","journal-title":"Nat Rev Dis Prim"},{"issue":"13","key":"10.1016\/j.apjo.2026.100380_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1167\/iovs.64.13.45","article-title":"Worldwide incidence of ocular melanoma and correlation with pigmentation-related risk factors","volume":"64","author":"Wu","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.apjo.2026.100380_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2024.100046","article-title":"Correlation of Fitzpatrick skin type and iris color with tumor size in 823 patients with uveal melanoma","volume":"13","author":"Agrawal","year":"2024","journal-title":"Asia Pac J Ophthalmol (Phila"},{"issue":"1","key":"10.1016\/j.apjo.2026.100380_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2023.100031","article-title":"Impact of iris color on uveal melanoma-related outcomes in 7245 patients at a single ocular oncology center","volume":"13","author":"Zaloga","year":"2024","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"12","key":"10.1016\/j.apjo.2026.100380_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009201","article-title":"Genomic and transcriptomic landscape of conjunctival melanoma","volume":"16","author":"Cisarova","year":"2020","journal-title":"PLoS Genet"},{"issue":"2","key":"10.1016\/j.apjo.2026.100380_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2024.100060","article-title":"Uveal melanoma: Current evidence on prognosis, treatment and potential developments","volume":"13","author":"Gelmi","year":"2024","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"2","key":"10.1016\/j.apjo.2026.100380_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2024.100047","article-title":"An optimized 3T MRI scan protocol to assess iris melanoma with subsequent histopathological verification \u2013 a prospective study","volume":"13","author":"Lim","year":"2024","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"5","key":"10.1016\/j.apjo.2026.100380_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2024.100108","article-title":"Gain of chromosome 8q and high expression of EZH2 may predict poor prognosis in Chinese patients with uveal melanoma","volume":"13","author":"Zhang","year":"2024","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"2","key":"10.1016\/j.apjo.2026.100380_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.apjo.2024.100062","article-title":"Targeted therapy in ophthalmic oncology: the current status","volume":"13","author":"Sen","year":"2024","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"2","key":"10.1016\/j.apjo.2026.100380_bib15","first-page":"179","article-title":"Uveal Melanoma: identifying immunological and chemotherapeutic targets to treat metastases","volume":"6","author":"Jager","year":"2017","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.apjo.2026.100380_bib16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/APO.0000000000000606","article-title":"Conjunctival melanoma in aotearoa-New Zealand: a 21-year analysis of incidence and survival","volume":"12","author":"Lim","year":"2023","journal-title":"Asia Pac J Ophthalmol (Phila)"}],"container-title":["Asia-Pacific Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162098926001064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162098926001064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:50:58Z","timestamp":1793382658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162098926001064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2162098926001064"],"URL":"https:\/\/doi.org\/10.1016\/j.apjo.2026.100380","relation":{},"ISSN":["2162-0989"],"issn-type":[{"value":"2162-0989","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can Moderna's mRNA cancer vaccine for cutaneous melanoma be applicable to melanomas of the eye and ocular adnexa?","name":"articletitle","label":"Article Title"},{"value":"Asia-Pacific Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apjo.2026.100380","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of Asia-Pacific Academy of Ophthalmology and Academy of Asia-Pacific Professors of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100380"}}